LGM
BPMC

Logos Global Management’s Blueprint Medicines BPMC Stock Holding History

Logos Global Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200,000
Closed -$17.4M – 44
2024
Q4 		$17.4M Buy
+200,000
New +$18.3M 2.04% 18
2020
Q2 		– Sell
-75,000
Closed -$4.39M – 51
2020
Q1 		$4.39M Buy
+75,000
New +$4.83M 1.67% 23

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Logos Global Management's BPMC Position: Q1 2025 in Review

Logos Global Management sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 200,000 shares — an estimated $17.4M sold.

Logos Global Management first reported a position in BPMC in Q1 2020 and held it in 2 quarters. The position peaked at $17.4M in Q4 2024. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

  • Logos Global Management reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
  • Logos Global Management sold 200,000 Blueprint Medicines shares in Q1 2025, an estimated $17.4M.
  • Logos Global Management first reported a position in Blueprint Medicines in Q1 2020 and held it in 2 quarters.
  • Logos Global Management's Blueprint Medicines position peaked at $17.4M in Q4 2024.
  • 352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on Logos Global Management's 13F filing for Q1 2025, filed 15 May 2025.